| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 15.61 | 11.66 | 21.73 | 7.18 |
Op profit growth | -6.93 | 46.13 | 3.78 | -4.14 |
EBIT growth | 1.23 | 33.63 | 9.12 | -4.09 |
Net profit growth | 8.99 | 39.8 | -0.2 | -7.53 |
Profitability ratios (%) | ||||
OPM | 27.81 | 34.55 | 26.4 | 30.97 |
EBIT margin | 27.52 | 31.43 | 26.26 | 29.3 |
Net profit margin | 21.33 | 22.62 | 18.07 | 22.04 |
RoCE | 28.1 | 30.82 | 27.88 | 33.49 |
RoNW | 5.69 | 5.84 | 5.03 | 6.49 |
RoA | 5.44 | 5.54 | 4.79 | 6.29 |
Per share ratios (₹) | ||||
EPS | 83.01 | 75.2 | 53.33 | 52.98 |
Dividend per share | 9.5 | 9.5 | 13 | 0 |
Cash EPS | 68.15 | 61.6 | 42.25 | 46.07 |
Book value per share | 378.77 | 343.14 | 295.23 | 229.95 |
Valuation ratios | ||||
P/E | 14.52 | 15.89 | 17.07 | 17.68 |
P/CEPS | 17.69 | 19.4 | 21.55 | 20.33 |
P/B | 3.18 | 3.48 | 3.08 | 4.07 |
EV/EBIDTA | 14.6 | 14.97 | 15.2 | 17.99 |
Payout (%) | ||||
Dividend payout | 11.53 | 12.67 | 24.78 | 0 |
Tax payout | -21.63 | -27.36 | -29.38 | -24.72 |
Liquidity ratios | ||||
Debtor days | 96.04 | 95.6 | 87.1 | 67.21 |
Inventory days | 85.07 | 79.71 | 59.68 | 48.21 |
Creditor days | -59.26 | -78.95 | -66.05 | -60.65 |
Leverage ratios | ||||
Interest coverage | -90.16 | -109.84 | -57.07 | -1,519.41 |
Net debt / equity | -0.05 | -0.05 | -0.05 | -0.04 |
Net debt / op. profit | -0.2 | -0.17 | -0.19 | -0.13 |
Cost breakup (₹) | ||||
Material costs | -24.91 | -22.32 | -25.33 | -19.11 |
Employee costs | -19.32 | -18.97 | -18.76 | -17.7 |
Other costs | -27.94 | -24.14 | -29.49 | -32.19 |
Profit after tax for the nine months ended December 2025 rose 14% year on year to ₹789 crore, compared with ₹695 crore in the year ago period
EBITDA margin for the quarter came in at 27.8%, slightly lower than 28% recorded in the year ago period.
The company plans to launch the product after securing all necessary regulatory approvals, which are expected to be received between late 2026 and early 2027.
Ajanta Pharma reported a strong EBITDA margin of 25% in the quarter.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
